Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales & Demand by Technology, Application & End-User The global 3d cell culture market will witness a robust CAGR of 16.3%, valued at $1.66 billion in 2021, expected to appreciate and reach $6.46 billion by 2030, confirms Strategic Market Research. North America surpassed the global industry in 2020, with a revenue share of more than 43%. 3D cell culture is a laboratory-created environment. A three-dimensional cell culture environment permits and allows biological cells to interact within their surroundings in all the three dimensions. In an in vitro state, 3D cell culture permits cells to grow in all directions. In terms of biological features & behaviour, cells grown in 3D cell culture, exhibit and demonstrate similar traits to cells found in real creatures. As the focus on drug development is rising, there is a requirement for cell culture in research and development. Moreover, the precision drug development techniques are gaining popularity which is also creating an impact on cell culture. Cancer based application for 3D cell culture is the fastest growing area and was valued at over $950 million in 2021. In 2021, based on technology, the scaffold-based segment ruled the overall 3D cell culture market and contributed to approximately two-fifth of the global market. Scaffold-based applications facilitate imaging, and the test technique is simple. Furthermore, during the forecast period of 2021-2030, the microchips segment is estimated to grow at the fastest CAGR of 21.3%. The cancer research segment held a significant position with the biggest market share and accounted for approximately one-third of the overall 3D cell culture market in 2021. It is anticipated that the adoption of the 3-dimensional cell models for the overall analysis of cancer biology in the preclinical screening and testing will boost revenue production in this market. Furthermore, the regenerative medicine segment will grow at a 19.5% CAGR during the forecast period of 2021-2030. On the basis of end-user, in 2021, the academic institute held the largest position contributing to one-third of the worldwide 3D cell culture market. It is estimated to lead the market in the near future because of the increased focus of academic institutes into R&D activities related to 3D culture models for the development of new approaches for the treatment of various medical conditions. However, the laboratories segment will grow at an 18.8% CAGR during 2021-2030. Biotechnology and pharmaceutical companies are also studied under end-user. In 2021, North America recorded the largest share and contributed to approximately two-fifth of the worldwide 3D cell culture market. The United States leads the 3D cell culture market in this region. The United States is concentrating on R&D and has recently made large investments in the research of 3D cell culture. Furthermore, with a CAGR of 19.8%, Asia Pacific is expected to be the fastest-growing market during 2021-2030. Cell culture is described as various laboratory techniques that allow eukaryotic or prokaryotic cells to develop in physiological settings. It was first used to research tissue growth and maturation, virus biology and vaccine creation, the function of genes in illness and health, and large-scale hybrid cell lines to manufacture biopharmaceuticals in the early twentieth century. Cultured cells have as many practical uses as cell types that can be produced in vitro. Cell culture is most typically used in clinical settings to create model systems for studying basic cell biology, replicating disease mechanisms, or testing the toxicity of new therapeutic molecules. The ability to modify genes and molecular pathways is one of the benefits of employing cell culture for these applications. Furthermore, the homogeneity of clonal cell populations or specific cell types and well-defined culture systems eliminates interfering genetic or environmental variables, allowing for high reproducibility and consistency in data generation that is impossible to guarantee when studying whole organ systems. Curi Bio's platform solutions facilitate faster development of therapies by combining human iPSC-derived cells, tissue-specific biosystems, and AI-enabled data analytics. The $6 million Series A funding round, led by Dynamk Capital, will help the company to build and verify its technology, demonstrating the need for predictive and mature human stem cell platforms to bridge the gap between preclinical and clinical outcomes. 3D cell culture is an in-vitro approach that involves creating an artificial environment and then allowing biological cells to develop, grow, or communicate using vascular endothelial growth factor and epidermal growth factor receptors with their environments in all three dimensions. A surge in cancer patients globally, rising investments, and growing incidence of infectious diseases primarily propel the market. Key Market Drivers - Rise in Infectious Diseases, Increasing Investments, and Expanding Emphasis on Healthcare Quality The global 3D cell culture market is being driven largely by its plethora of applications in drug screening through high-throughput screening, regenerative medicine, drug repositioning while taking care of pharmacology and toxicology, stem cell treatments, 3D cell culture cancer research, and cell biology. According to a research study, differences in T-DM1 drug action in 3D spheroids or aggregates could be attributed to tumour heterogeneity and less effective T-DM1 internalization, which is not evident in 2D cell culture models. In future drug response and resistance research, 3D cell culture experiments will provide biologically appropriate models for assessing drug screening activities in tumour tissue. Furthermore, the sector benefits from the increasing use of 3D cell culture models as an alternative approach for in vivo testing, research and development of extended cell culture systems, and increased demand for organ transplantation. In addition to this, the rise in infectious illnesses has prompted the development of antiviral medications, bioreactors, cell-based treatments through primary cell culture and animal tissue culture, and vaccinations employing cell culture techniques. According to the CDC, TB bacteria afflicted 1.7 billion individuals or roughly 23% of the world's population. TB is the principal cause of fatality worldwide, claiming 1.5 million lives each year. The desire for cell-based vaccinations has grown since the procedure generates vaccines in the lowest time and is not restricted by the choice of vaccine viruses suited for eggs' development. Moreover, the expanding emphasis on healthcare quality, the growing concern about the rise of microfluidics-based 3D cell culture methods, increasing investment for technical advancement, and the launch of new products contribute to the market's overall expansion. To stimulate the growth of its biopharmaceutical contract development and manufacturing business, FUJIFILM Corporation is investing more than $2 billion in a new large-scale cell culture production site in the United States (CDMO). According to the findings of the Centers for Medicare & Medicaid Services, the federal government's healthcare spending climbed 36.0 % in 2020, compared to 5.9% in 2019. The COVID-19 pandemic contributed significantly to this sudden upsurge in growth. Hospital spending rose to 6.4 % to $1,270.1 billion in 2020, faster than the 6.3 % growth in 2019. Market Restraints - Higher Cost of Technology, Availability of Substitutes, and Lack of Trained Professionals Lack of skilled professionals, availability of substitutes such as 2D cell culture, and higher cost of the technologies will hamper the growth of the 3D cell culture industry. Opportunities: - Rising Awareness, Increasing Investment and R&D Recent developments in neuromuscular-reproducing in-vitro systems, enabled by 3D cell-culture methods, have improved reliability. Furthermore, advancements in 3D cell culture for recreating the whole spinal-locomotion circuit and neurodegenerative processes are expected to generate a good potential for global industry expansion. Increasing awareness, an increase in the funding in stem cell research, and the expanding use of 3D cell culture in cancer therapy, cell-based biosensors, 3D cell culture assays for in vitro (3D cell culture organoid) evaluation of anti-cancer drugs, 4D cell culture might all contribute to a market spike throughout the review period. The Hon Greg Hunt, the Federal Minister for Health and Aged Care, allocated funding of $18.7 million for the 2020 Stem Cell Mission, which is focused on developing and delivering novel, safe, and effective stem cell treatments to enhance health outcomes. The University of Sydney had been given $6.3 million for three studies that will treat adult blindness and chronic heart disease and help to enhance judgments about stem cell interventions. Market Analysis Of Different Segments Covered in the Report Based on Technology Scaffold-based Hydrogels Polymeric Scaffolds Micro-patterned Surface Microplates Nanofiber-based Scaffolds Scaffold-free Hanging Drop Microplates Microfluidic 3D Cell Culture Spheroid Microplates with ULA coating Magnetic Levitation & 3D Bioprinting Bioreactors Based on Application Cancer Tissue Engineering & Immunohistochemistry Drug Development Stem Cell Research Others Based on End-User Biotechnology and Pharmaceutical Industries Research Laboratories and Institutes Hospitals and Diagnostic Centers Others Regional Coverage Analysis North America USA Canada Mexico Rest of North America Europe Germany UK France Switzerland Russia Rest of Europe Asia-Pacific India China Japan Rest of Asia pacific LAMEA Brazil Argentina UAE Rest of LAMEA Technology Analysis & Insights Scaffold-based technology had the highest revenue share of more than 68.96% in 2020. In 3-dimensional cell culture-based research, using hydrogels as scaffolds allows the integration of complex biochemical and mechanical signals that mimic the natural extracellular matrix. Furthermore, the increased popularity and awareness of nanotechnology in biomedical research is expected to offer future growth opportunities for nanofiber-based scaffolds, consequently increasing customer preference for scaffold-based technology. The National Institutes of Health announced an investment of $445 million in nanomedicine in 2020. The National Nanotechnology Initiative got more than $1.7 billion in funding in 2021. As a result, it will further augment the growth of the 3D cell culture scaffold market. Application Analysis & Insights In 2020, the Cancer sector led the market, accounting for 24.56% of total revenue, and is projected to grow at a CAGR of 15.4%. R&D in this industry is driven by using spheroids as model systems to develop anti-cancer treatments. The National Cancer Institute estimated that there were 16.9 million cancer survivors in the United States in 2020, and by 2030, the number of cancer survivors is expected to reach 22.2 million. Moreover, using 3-dimensional cellular models to study cancer in preclinical testing and screening is expected to increase the revenue generation of this segment. A research article published in January 2021 announced the creation of polysaccharide hydrogel-based 3D printed tumour models can be utilized for high throughput screening of anti-cancer medications. Moreover, from 2021 to 2030, the stem cell research segment is predicted to foster a robust growth rate. End-user Analysis & Insights In 2020, the biotechnology and pharmaceutical industries category produced the highest revenue share of more than 46%. Compared to 2D cell culture, different types of 3D cell culture have benefits in terms of appropriate oxygen and nutritional gradients, non-uniform exposure of cells within a spheroid to a drug, and realistic cell-to-cell interactions. Because of these qualities, 3D cell cultures are more suited for drug discovery and development, which drives demand. Region Analysis & Insights North America dominated the global 3D cell culture market in 2020, with more than 43 % revenue share. The region will lead throughout the forecasted period because of private and state financial support for developing advanced 3D cell culture models, high healthcare spending, and the increased number of universities and research organizations investigating various stem cell-based approaches. Blackbird Ventures led a $25 million Series B fundraising round for Inventia Life Science, a global leader in advanced 3D cell cultures for research and clinical uses. Inventia also announced the start of its operations in the United States. Inventia intends to use this Series B round of funding to commercialize its RASTRUM 3D cell culture technology globally and expand its team from 36 to 150 workers by 2024. It intends to establish a substantial presence in the United States, where the biomedical research and drug discovery sectors are valued at more than $40 billion. The Series B round raises Inventia's total funding to $32 million. However, Asia Pacific will witness the fastest regional market from 2021 to 2030 due to increased investments by various multinational corporations in the region's rising economies. 3D Cell Culture Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 Market size value in 2021 USD 1.66 billion Revenue forecast in 2030 USD 6.47 billion Growth rate CAGR of 16.3 % The base year for estimation 2020 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Technology, By Application, By End Users, By Region. By Technology Scaffold-based, Scaffold-free, Bioreactors By Application Cancer, Tissue Engineering & Immunohistochemistry, Drug Development, Stem Cell Research, Others By End-User Biotechnology and Pharmaceutical Industries, Research Laboratories and Institutes, Hospitals and Diagnostic Centers, Others By Region Europe, Asia Pacific, North America, and LAMEA Country Scope US, Brazil, Canada, Germany, UK, France, China, Japan, India etc. Company Usability Profiles Merck KGaA, Thermo Fisher Scientific, Inc., PromoCell GmbH, Greiner Bio One International GmbH, Corning, Inc., 3D Biomatrix, Lonza, Avantor Performance Materials, LLC, Tecan Trading AG, 3D Biotek LLC Global 3D Cell Culture Market Competitive Landscape Analysis The competitive landscape analysis gives an overview of some prominent players operating in the market. Product innovation and continued R&D operations to create sophisticated technologies have assisted the industry growth. In the target industry, some of the leading 3D cell culture companies are: Merck KGaA Thermo Fisher Scientific, Inc. PromoCell GmbH Greiner Bio One International GmbH Corning, Inc. 3D Biomatrix Lonza Avantor Performance Materials, LLC Tecan Trading AG 3D Biotek LLC Global Cell Solutions, Inc. InSphero Recent Developments: On December 2021, CellPort Software, a SaaS firm that digitizes cell development and production workflows, joined the Tetra Partner Network (TPN) to speed the delivery of cell-based medicines, according to TetraScience, the R&D Data Cloud company. CellPort is dedicated for the creation of scientific data liquidity. TetraScience's platform conveniently connects laboratory items to CellPort's software via this agreement, allowing users to swiftly construct innovative, new processes and acquire critical insights into cell lines. On January 2021, Adocia created a novel hydrogel to host and protect pancreatic cell implants. This hydrogel scaffold containing pancreatic cells has the potential to restore glycemic control without the need for insulin injections or immunosuppressive medications. An academic partnership has been created with Pr. Pattou's Inserm Team, the global leader in islet transplant, to develop this product in animal models and, eventually, in humans. On December 2020, eNUVIO announced the launch of market's first entirely reusable 3D cell culture microplate. The introduction of eNUVIO's entirely reusable EB-Plate in the market comes at an ideal time; since there is a significant demand for 3D cell culture microplates. Traditional plastic plates are now in limited supply, and the zero-waste campaign is gaining traction in laboratories. Furthermore, the manufacturers claim that the new plates pay for themselves after 5-8 uses and may be reused many times more. Various 3D Cell Culture Commercial Products that the Market Leaders are Manufacturing Name Feature Key Player Corning CoolCell In conjunction with a -80°C freezer, the Corning CoolCell will deliver alcohol-free freezing at a rate of -1°C/minute, appropriate for the cryopreservation of most cells and cell lines. Corning Gibco FreeStyle F17 A chemically defined, protein-free, serum-free media designed to enable the suspension growth and transfection of HEK293 cells. Before usage, 4–8 mM L-glutamine or GlutaMAX supplementation is recommended. Thermo Fisher Scientific, Inc. GrowDex A bio-friendly hydrogel derived from birch and produced from properly maintained forests, GrowDex is a ready-to-use hydrogel that replicates the extracellular matrix (ECM), promoting continuous cell growth and differentiation. UPM Biomedicals Frequently Asked Question About This Report Which are the top companies that hold the market share in the market? Merck KGaA, Thermo Fisher Scientific, Inc., PromoCell GmbH, Greiner Bio-One International GmbH, Corning, Inc., and 3D Biomatrix are some of the leading companies. What is the 3d cell culture market growth? The global 3d cell culture market is expected to grow at a compound annual growth rate (CAGR) of 16.3% from 2021 to 2030 to reach $6.46 Billion by 2030. What are the factors driving the market? Hike in the number of cancer patients globally, rising investments, and growing incidence of infectious diseases are primarily driving the market. How big is the 3d cell culture market? The global 3d cell culture market size was $1.66 Billion in 2021 and is predicted to reach $6.46 Billion by 2030 with a CAGR of 16.3%. Sources https://www.cdc.gov/globalhealth/newsroom/topics/tb/index.html https://fujifilmdiosynth.com/about-us/press-releases/fujifilm-to-invest-over-200-billion-yen-2-billion-usd-to-establish-new-large-scale-cell-culture-manufacturing-site-for-biopharmaceuticals-in-the-u-s-a/ https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NHE-Fact-Sheet https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/180-million-in-medical-research-to-improve-the-lives-of-australians https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464102/ https://cancercontrol.cancer.gov/ocs/statistics 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 3D Cell Culture Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global 3D Cell Culture Market 4.2.1 Global market, 2021 – 2030 (USD Million) 4.3 Regional Analysis 4.3.1 market, by region, 2021-2030 (USD Million) 4.4 By Technology Analysis 4.4.1 market, By Technology, 2021-2030 (USD Million) 4.5 By End-User Analysis 4.5.1 market, By End-User, 2021-2030 (USD Million) 4.6 Application Analysis 4.6.1 market, By Application, 2021-2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 market PEST analysis 4.9.2 market Porter’s analysis 4.10 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Application Analysis 5.11.1. Trends in Application (2021-2030) 5.11.2. Trends in Application (2021-2030) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers, Area Served, Technology Technology 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global 3D Cell Culture Market: By Technology Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Scaffold-based 7.3.1. Scaffold-based market, 2021-2030 (USD Million) 7.3.1.1 Hydrogels market, 2021-2030 (USD Million) 7.3.1.2 Polymeric Scaffolds market, 2021-2030 (USD Million) 7.3.1.3 Micro-patterned Surface Microplates market, 2021-2030 (USD Million) 7.3.1.4 Nanofiber-based Scaffolds market, 2021-2030 (USD Million) 7.4. Scaffold-free 7.4.1 Hanging Drop Microplates market, 2021-2030 (USD Million) 7.4.1.1 Hanging Drop Microplates market, 2021-2030 (USD Million) 7.4.1.2 Microfluidic 3D Cell Culture market, 2021-2030 (USD Million) 7.4.1.3 Spheroid Microplates with ULA coating market, 2021-2030 (USD Million) 7.4.1.4 Magnetic Levitation & 3D Bioprinting market, 2021-2030 (USD Million) 7.5. Bioreactors 7.5.1. Bioreactors market, 2021-2030 (USD Million) 8. Global 3D Cell Culture Market: By End-User Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Biotechnology and Pharmaceutical Industries 8.3.1. Biotechnology and Pharmaceutical Industries market, 2021-2030 (USD Million) 8.4. Research Laboratories and Institutes 8.4.1. Research Laboratories and Institutes market, 2021-2030 (USD Million) 8.5. Hospitals and Diagnostic Centers 8.5.1. Hospitals and Diagnostic Centers market, 2021-2030 (USD Million) 8.6. Others 8.6.1. Others market, 2021-2030 (USD Million) 9. Global 3D Cell Culture Market: By Application Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Cancer 9.3.1. Cancer Market, 2021-2030 (USD Million) 9.4. Tissue Engineering & Immunohistochemistry 9.4.1. Tissue Engineering & Immunohistochemistry Market, 2021-2030 (USD Million) 9.5. Drug Development 9.5.1. Drug Development Market, 2021-2030 (USD Million) 9.6. Stem Cell Research 9.5.1. Stem Cell Research Market, 2021-2030 (USD Million) 9.7. Others 9.5.1. Others Market, 2021-2030 (USD Million) 10. Global 3D Cell Culture Market: Regional Outlook 10.1 North America 10.1.1. North American market, by By Technology, 2021-2030 (USD Million) 10.1.2. North American market, by By End-User, 2021-2030 (USD Million) 10.1.3. North American market, by Application, 2021-2030 (USD Million) 10.1.4. North American market, by Country, 2021-2030 (USD Million) 10.1.4.1. U.S. 10.1.4.1.1. U.S. market, by By Technology, 2021-2030 (USD Million) 10.1.4.1.2. U.S. market, by By End-User, 2021-2030 (USD Million) 10.1.4.1.3. U.S. market, by Application, 2021-2030 (USD Million) 10.1.4.2. Canada 10.1.4.2.1. Canada market, by By Technology, 2021-2030 (USD Million) 10.1.4.2.2. Canada market, by By End-User, 2021-2030 (USD Million) 10.1.4.2.3. Canada market, by Application, 2021-2030 (USD Million) 10.2. Europe 10.2.1. European market, by By Technology, 2021-2030 (USD Million) 10.2.2. European market, by By End-User, 2021-2030 (USD Million) 10.2.3. European market, by Application, 2021-2030 (USD Million) 10.2.4. European market, by country, 2021-2030 (USD Million) 10.2.4.1 U.K. 10.2.4.1.1. U.K. market, by By Technology, 2021-2030 (USD Million) 10.2.4.1.2. U.K. market, by By End-User, 2021-2030 (USD Million) 10.2.4.1.3. U.K. market, by Application, 2021-2030 (USD Million) 10.2.4.2. Germany 10.2.4.2.1. Germany market, by By Technology, 2021-2030 (USD Million) 10.2.4.2.2. Germany market, by By End-User, 2021-2030 (USD Million) 10.2.4.2.3. Germany market, by Application, 2021-2030 (USD Million) 10.2.4.3. France 10.2.4.3.1. France market, by By Technology, 2021-2030 (USD Million) 10.2.4.3.2. France market, by By End-User, 2021-2030 (USD Million) 10.2.4.3.3. France market, by Application, 2021-2030 (USD Million) 10.2.4.4. Rest of Europe 10.2.4.4.1. Rest of European market, by By Technology, 2021-2030 (USD Million) 10.2.4.4.2. Rest of European market, by By End-User, 2021-2030 (USD Million) 10.2.4.4.3. Rest of European market, by Application, 2021-2030 (USD Million) 10.3. Asia Pacific 10.3.1. Asia Pacific market, by By Technology, 2021-2030 (USD Million) 10.3.2. Asia Pacific market, by By End-User, 2021-2030 (USD Million) 10.3.3. Asia Pacific market, by Application, 2021-2030 (USD Million) 10.3.4. Asia Pacific market, by country, 2021-2030 (USD Million) 10.3.4.1. China 10.3.4.1.1. China market, by By Technology, 2021-2030 (USD Million) 10.3.4.1.2. China market, by By End-User, 2021-2030 (USD Million) 10.3.4.1.3. China market, by Application, 2021-2030 (USD Million) 10.3.4.2. India 10.3.4.2.1. India market, by By Technology, 2021-2030 (USD Million) 10.3.4.2.2. India market, by By End-User, 2021-2030 (USD Million) 10.3.4.2.3. India market, by Application, 2021-2030 (USD Million) 10.3.4.3. Japan 10.3.4.3.1. Japan market, by By Technology, 2021-2030 (USD Million) 10.3.4.3.2. Japan market, by By End-User, 2021-2030 (USD Million) 10.3.4.3.3. Japan market, by Application, 2021-2030 (USD Million) 10.3.4.4. South Korea 10.3.4.4.1. South Korea market, by By Technology, 2021-2030 (USD Million) 10.3.4.4.2. South Korea market, by By End-User, 2021-2030 (USD Million) 10.3.4.4.3. South Korea market, by Application, 2021-2030 (USD Million) 10.3.4.5. Rest of ASIA PACIFIC 10.3.4.5.1. Rest of ASIA PACIFIC market, by By Technology, 2021-2030 (USD Million) 10.3.4.5.2. Rest of ASIA PACIFIC market, by By End-User, 2021-2030 (USD Million) 10.3.4.5.3. Rest of ASIA PACIFIC market, by Application, 2021-2030 (USD Million) 10.4. Latin America 10.4.1. Latin America market, by By Technology, 2021-2030 (USD Million) 10.4.2. Latin America market, by By End-User, 2021-2030 (USD Million) 10.4.3. Latin America market, by Application, 2021-2030 (USD Million) 10.4.4. Latin America market, by country, 2021-2030 (USD Million) 10.4.4.1. Brazil 10.4.4.1.1. Brazil market, by By Technology, 2021-2030 (USD Million) 10.4.4.1.2. Brazil market, by By End-User, 2021-2030 (USD Million) 10.4.4.1.3. Brazil market, by Application, 2021-2030 (USD Million) 10.4.4.2. Mexico 10.4.4.2.1. Mexico market, by By Technology, 2021-2030 (USD Million) 10.4.4.2.2. Mexico market, by By End-User, 2021-2030 (USD Million) 10.4.4.2.3. Mexico market, by Application, 2021-2030 (USD Million) 10.4.4.3. Rest of Latin America 10.4.4.3.1. Rest of the Latin America market, by By Technology, 2021-2030 (USD Million) 10.4.4.3.2. Rest of the Latin America market, by By End-User, 2021-2030 (USD Million) 10.4.4.3.3. Rest of the Latin America market, by Application, 2021-2030 (USD Million) 10.5. MEA 10.5.1. MEA market, by By Technology, 2021-2030 (USD Million) 10.5.2. MEA market, by By End-User, 2021-2030 (USD Million) 10.5.3. MEA market, by Application, 2021-2030 (USD Million) 10.5.4. MEA market, by Region, 2021-2030 (USD Million) 11. Competitive Landscape 11.1 Merck KGaA. 11.1.1. Company overview 11.1.2. Financial performance 11.1.3. Product Portfolio Analysis 11.1.4. Business Strategy & Recent Development 11.2 Thermo Fisher Scientific, Inc. 11.2.1. Company overview 11.2.2. Financial performance 11.2.3. Product Portfolio Analysis 11.2.4. Business Strategy & Recent Development 11.3. PromoCell GmbH 11.3.1. Company overview 11.3.2. Financial performance 11.3.3. Product Portfolio Analysis 11.3.4. Business Strategy & Recent Development 11.4. Greiner Bio One International GmbH 11.4.1. Company overview 11.4.2. Financial performance 11.4.3. Product Portfolio Analysis 11.4.4. Business Strategy & Recent Development 11.5. Corning, Inc. 11.5.1. Company overview 11.5.2. Financial performance 11.5.3. Product Portfolio Analysis 11.5.4. Business Strategy & Recent Development 11.6. 3D Biomatrix . 11.6.1. Company overview 11.6.2. Financial performance 11.6.3. Product Portfolio Analysis 11.6.4. Business Strategy & Recent Development 11.7. Lonza 11.7.1. Company overview 11.7.2. Financial performance 11.7.3. Product Portfolio Analysis 11.7.4. Business Strategy & Recent Development 11.8. Avantor Performance Materials, LLC 11.8.1. Company overview 11.8.2. Financial performance 11.8.3. Product Portfolio Analysis 11.8.4. Business Strategy & Recent Development 11.9. Tecan Trading AG 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.10. 3D Biotek LLC 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.11. Global Cell Solutions, Inc. 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.12. InSphero 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development List of Tables (57 Tables) TABLE 1. MARKET, By Technology, 2021-2030 (USD Million) TABLE 2. MARKET FOR Scaffold-based, BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Scaffold-free, BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Bioreactors, BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET, By End-User, 2021-2030 (USD Million) TABLE 6. MARKET FOR Biotechnology and Pharmaceutical Industries, BY REGION, 2021-2030 (USD Million) TABLE 7. MARKET FOR Research Laboratories and Institutes, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET FOR Hospitals and Diagnostic Centers, BY REGION, 2021-2030 (USD Million) TABLE 9. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 11. MARKET FOR Cancer, BY REGION, 2021-2030 (USD Million) TABLE 12. MARKET FOR Tissue Engineering & Immunohistochemistry, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET FOR Drug Development, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET FOR Stem Cell Research, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 16. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 17. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 18. NORTH AMERICA MARKET, By Technology, 2021-2030 (USD Million) TABLE 19. NORTH AMERICA MARKET, By End-User, 2021-2030 (USD Million) TABLE 20. NORTH AMERICA MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 21. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 22. EUROPE MARKET, By Technology, 2021-2030 (USD Million) TABLE 23. EUROPE MARKET, By End-User, 2021-2030 (USD Million) TABLE 24. EUROPE MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 25. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 26. ASIA-PACIFIC MARKET, By Technology, 2021-2030 (USD Million) TABLE 27. ASIA-PACIFIC MARKET, By End-User, 2021-2030 (USD Million) TABLE 28. ASIA-PACIFIC MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 29. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 30. LAMEA MARKET, By Technology, 2021-2030 (USD Million) TABLE 31. LAMEA MARKET, By End-User, 2021-2030 (USD Million) TABLE 33. LAMEA MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 34. Merck KGaA: COMPANY SNAPSHOT TABLE 35. Merck KGaA: OPERATING SEGMENTS TABLE 36. Thermo Fisher Scientific, Inc COMPANY SNAPSHOT TABLE 37. Thermo Fisher Scientific, Inc OPERATING SEGMENTS TABLE 38. PromoCell GmbH. COMPANY SNAPSHOT TABLE 39. PromoCell GmbH. OPERATING SEGMENTS TABLE 40. Greiner Bio One International GmbH..: COMPANY SNAPSHOT TABLE 41. Greiner Bio One International GmbH. OPERATING SEGMENTS TABLE 42. Corning, Inc.: COMPANY SNAPSHOT TABLE 43. Corning, Inc.: OPERATING SEGMENTS TABLE 44. 3D Biomatrix. COMPANY SNAPSHOT TABLE 45. 3D Biomatrix. OPERATING SEGMENTS TABLE 46. Lonza .COMPANY SNAPSHOT TABLE 47. Lonza. OPERATING SEGMENTS TABLE 48. Avantor Performance Materials, LLC: COMPANY SNAPSHOT TABLE 49. Avantor Performance Materials, LLC: OPERATING SEGMENTS TABLE 50. Tecan Trading AG. COMPANY SNAPSHOT TABLE 51. Tecan Trading AG. OPERATING SEGMENTS TABLE 52. 3D Biotek LLC. COMPANY SNAPSHOT TABLE 53. 3D Biotek LLC. OPERATING SEGMENTS TABLE 54. Global Cell Solutions, Inc. COMPANY SNAPSHOT TABLE 55. Global Cell Solutions, Inc.. OPERATING SEGMENTS TABLE 56. InSphero.. COMPANY SNAPSHOT TABLE 57. InSphero. OPERATING SEGMENTS List of Figures (22 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Technology-Based Estimation Figure 6 Top 12 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for 3D Cell Culture, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for 3D Cell Culture, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By End-User, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By Application, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Technology, 2019 vs. 2025 (USD Million) Figure 14 Geographical Snapshot of the Market Figure 15 Scaffold-based to Witness Higher CAGR in Market for Technology Segment during Forecast Period. Figure 16 Cancer to Witness Higher CAGR in Market for Application Segment during Forecast Period. Figure 17 Biotechnology and Pharmaceutical Industries to Witness Higher CAGR in Market for End-User Segment during Forecast Period. Figure 18 North America region Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges Figure 20 North America: Market Snapshot Figure 21 Asia Pacific: Market Snapshot Figure 22 Vendor Dive: Evaluation Overview